Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

1-s2.0-S001425652500133X-main.pdf (463.29 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-10-31

Llicència de publicació

cc-by-nc (c) Villanueva, Bernat et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/226913

Evolución de biomarcadores de angiogénesis e inflamación en pacientes con telangiectasia hemorrágica hereditaria durante el tratamiento con bevacizumab: protocolo de estudio

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.rce.2025.502370

Resum

Background: Hereditary hemorrhagic telangiectasia (HHT) is a rare disease characterized by mucocutaneous telangiectasia and visceral vascular malformations. Treatment with bevacizumab is recommended in patients with liver involvement and high output cardiac failure (HOCF) or those with severe gastrointestinal (GI) involvement. However, there is no evidence on how to monitor such treatment using biomarkers. Material and methods: This is an exploratory, observational, prospective, single-center study carried out in an HHT referral unit. The inclusion period for the start of bevacizumab was from January 2022 to May 2023. Patients with an indication for starting bevacizumab were selected and underwent blood tests at baseline and during the induction (36 weeks) and maintenance phase in order to analyze 21 biomarkers related to angiogenesis and inflammation. In addition, control HHT patients without indication for bevacizumab and healthy controls matched 1:1:1 by age, sex, and genetic subtype (for HHT patients) underwent a baseline biomarker study. The main objective is to analyze the evolution of these biomarkers in patients with HHT treated with bevacizumab. As secondary objectives, baseline differences in the concentration of these biomarkers between the three groups and correlation with the hemoglobin levels will be analyzed. Groups description: During the study period, nine patients with an indication for bevacizumab were included, seven due to anemia of GI origin and two due to liver involvement with HOCF, with an overall mean age of 70 +/- 8.4 years, and subsequently the respective nine patients with HHT without bevacizumab and nine controls without HHT were selected. Conclusions: The results of this exploratory study will provide new knowledge regarding potential biomarkers for monitoring the response to treatment with bevacizumab. Furthermore, it could generate new hypotheses about the role of certain biomarkers at the pathophysiological, diagnostic, and therapeutic levels. (c) 2025 The Authors. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Matèries

Malalties arterials, Arteritis, Tromboembolisme

Matèries (anglès)

Arteries Diseases, Arteritis, Thromboembolism

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

VILLANUEVA, Bernat, et al. Evolución de biomarcadores de angiogénesis e inflamación en pacientes con telangiectasia hemorrágica hereditaria durante el tratamiento con bevacizumab: protocolo de estudio. Revista Clínica Española. 2025. Vol. 225, num. 9, pags. 502370. ISSN 0014-2565. [consulted: 4 of August of 2026]. Available at: https://hdl.handle.net/2445/226913

Exportar metadades

JSON - METS

Compartir registre